This Roche-sponsored scientific symposium covered topics from the lab through to the clinic, including differences between clotting factor VIII and IX deficiencies in female carriers and their underlying mechanisms, as well as the unmet clinical needs of women and girls with haemophilia. Furthermore, discrepancies among clotting factor activity assays, their impact on factor replacement therapy and practical solutions to address those were discussed. Finally, the various reasons for and the impact of a delayed diagnosis of rare bleeding disorders, focusing on women, infants and mobile populations, were examined.
Roche at ISTH 2022
Advances in diagnosis and management of bleeding disorders
Roche-sponsored symposium recording
Meet the speakers
Alok Srivastava
MD, FRACP, FRCPA, FRCP
Alok Srivastava is a Professor of Medicine in the Department of Haematology, and head of the Centre for Stem Cell Research at the Christian Medical College (CMC), Vellore in India.
Dr Srivastava has been involved with the management of patients with bleeding disorders for over 25 years. His group has worked extensively on developing genetic diagnosis of bleeding disorders and clinical protocols for their management which address the needs of developing countries. Their recent focus has also included assessment of novel therapies in different clinical trials with a major program for developing gene therapy for haemophilia. He leads the World Federation of Hemophilia designated International Hemophilia Training Center at CMC, Vellore. Dr Srivastava is President of the Indian Association for Haemophilia & Allied Disorders. He is also the chair of the steering committee of the Association for Haemophilia & Allied Disorders – Asia-Pacific. He was the chair of the FVIII/IX subcommittee of the Scientific and Standardization Committee (SSC),
International Society of Thrombosis and Haemostasis (ISTH) from 2006-2010. He was on the board of the WFH from 2002-2014 and served as the Vice-President (Medical) from 2012-2014. He has led the writing group for all three editions of the WFH guidelines for the management of haemophilia.
Annette Bowyer
PhD in Cardiovascular Science
Annette Bowyer is the Scientific Lead for Haemophilia Assays in the Department of Coagulation at Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK, which has been designated an International Haemophilia Training Centre by the World Federation of Haemophilia.
Dr Bowyer was awarded her PhD in Cardiovascular Science from the University of Sheffield, UK, with a thesis focussing on the laboratory diagnosis of mild haemophilia A, and has more than 20 years of experience in the diagnosis and monitoring of bleeding disorders. Her current interest is in laboratory issues surrounding treatment products for haemophilia and von Willebrand disease. Dr Bowyer is a member of both the UK Haemophilia Centre Doctors’ Organisation (UKHCDO) Laboratory Working Party and the World Federation of Haemophilia laboratory working party, a fellow of the Institute of Biomedical Science, and a member of the International Society on Thrombosis and Haemostasis and the European Association for Haemophilia and Allied Disorders.
Cedric Hermans
MD, PhD, FRCP
Cedric Hermans currently heads the Division of Haematology, the Haemostasis and Thrombosis Unit as well as the Hemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium. He was appointed Associate Professor at the Medical School of the Catholic University of Louvain in 2003, Full Professor in 2012 and Vice-Dean in 2015. Professor Hermans has (co)-authored more than 300 original articles in international journals and is a member of several scientific societies and international advisory boards and collaborative research projects. He was president of EAHAD and is currently a member of the Board of Directors of the World Federation of Haemophilia and the Editor-in-Chief of the Haemophilia Journal. His main research interests lie in the area of haemostasis and thrombosis, especially clinical studies on the treatment modalities and the wide spectrum of complications of haemophilia in both developed and developing countries, as well as new anticoagulants and the management of thrombosis.
Andreas Tiede
Professor of Haemostasis and Thrombosis
Andreas Tiede is a Professor of Haemostasis and Thrombosis, Head of the Haemophilia Care Centre the Central Hematology Laboratory at Hannover Medical School in Hannover, Germany. His main areas of interest for basic and clinical research include congenital and acquired disorders of haemostasis, classical hematology and laboratory hematology. He is Associate Editor of “Annals of Hematology” and “Thrombosis and Haemostasis”.
Paula H.B.Bolton-Maggs
FRCP, FRCPath, DM
Paula H.B.Bolton-Maggs was Medical Director of the Serious Hazards of Transfusion (SHOT) national haemovigilance scheme from October 2011 to August 2018 and is currently an Honourary Senior Lecturer in the Faculty of Biology, Medicine and Health at Manchester University since 2003.
Dr Bolton-Maggs has a longstanding interest in haemostasis; most recently she was responsible for the collation and analysis of the UK adverse incidents relating to blood transfusion (website www.shotuk.org). She received the Mollison award from the British Blood Transfusion Society in 2018 in recognition of her contribution to haemovigilance, was secretary of the International Haemovigilance Network from 2011 to 2018 and received the IHN Medal for her contribution.
Dr Bolton-Maggs has researched for 25 years, especially in the area of factor XI deficiency and has a major interest in rare bleeding disorders. She has taken the lead on and contributed to several national guidelines in this field, published by the British Society for Haematology.
